Doximity (DOCS)

NYSE Health Care Health Care Technology S&P MidCap 400
$32.51
-0.67 (-2.02%)
Close of Nov 06, 2026 · end-of-day data
SMA 50SMA 2005Y/10Y use weekly candles (10/40-week averages)

Performance

price return
1W-0.8%
1M+10.7%
3M+26.8%
6M+25.1%
YTD-26.6%
1Y-49.2%
3Y+59.9%
5Y-53.2%

Key statistics

Full financials →
Market cap$5.8B
P/E (TTM)45.2
EPS (TTM, diluted)$0.72
P/S8.76
P/B6.24
EV / EBITDA29.2
Revenue (TTM)$662.00M
Revenue growth+6.5%
Net margin21.1%
ROE15.0%
Debt / equity0.00
FCF yield5.3%
Dividend yield—
Payout ratio—
Beta (1Y)0.57
Volatility (1Y)64.5%
52-week range$17.15 – $64.55
Avg volume (50D)2.88M

Revenue & net income — last 8 quarters

Statements →
Nov 5, 4:04 PM ET

Doximity Q2 revenue rises 4% to $174.5 million; net income falls to $34.7 million

Mixed earnings 2.02

Doximity reported fiscal second-quarter revenue of $174.5 million, up 4% from a year earlier, but net income fell to $34.7 million from $62.1 million and adjusted EBITDA declined 12% to $88.9 million. The company also gave fiscal third-quarter and updated full-year fiscal 2027 guidance, which shareholders can compare against these results.

  • Revenue of $174.5 million versus $168.5 million, up 4% year-over-year
  • Net income of $34.7 million versus $62.1 million; diluted EPS of $0.18 versus $0.31
  • Adjusted EBITDA of $88.9 million versus $100.8 million, down 12%; margin 50.9% versus 59.8%
  • Fiscal 2027 revenue guidance of $678 million to $683 million and adjusted EBITDA of $317 million to $325 million; third-quarter revenue guidance of $195 million to $196 million
Read the filing on SEC.gov ↗
Aug 6, 4:04 PM ET

Doximity revenue rises 7% to $156.6 million; net income falls to $24.3 million

Mixed earnings Written later 2.02

Doximity reported fiscal first-quarter 2027 results for the quarter ended June 30, 2026, with revenue up 7% year-over-year but net income and adjusted EBITDA both lower than a year earlier. The company also gave revenue and adjusted EBITDA guidance for its fiscal second quarter and updated its full fiscal 2027 outlook, so shareholders face a mix of growth and declining profit.

  • Revenue was $156.6 million, up 7% from $145.9 million a year earlier.
  • Net income was $24.3 million, down from $53.3 million; diluted EPS was $0.13 versus $0.27.
  • Adjusted EBITDA was $74.8 million, down 6% from $79.8 million; free cash flow was $39.6 million, down 34%.
  • Guidance: fiscal Q2 revenue of $170 million to $171 million; fiscal 2027 revenue of $671 million to $681 million and adjusted EBITDA of $309 million to $329 million.
Read the filing on SEC.gov ↗
May 13, 4:04 PM ET

Doximity Q4 revenue up 5% to $145.4 million; net income falls; new CFO named

Mixed earnings Written later 2.025.02

Doximity reported fiscal fourth-quarter 2026 revenue of $145.4 million, up 5%, but GAAP net income fell to $19.1 million from $62.5 million and adjusted EBITDA declined 6%. The company also gave fiscal 2027 revenue guidance of $664 million to $676 million and named Matthew Sonefeldt as chief financial officer and Steven L. Zatz, M.D. as president, both effective May 13, 2026.

  • Q4 revenue $145.4 million vs. $138.3 million; net income $19.1 million vs. $62.5 million; diluted EPS $0.10 vs. $0.31
  • Q4 adjusted EBITDA $65.8 million vs. $69.7 million; full-year fiscal 2026 revenue $644.9 million, up 13%
  • Fiscal 2027 guidance: revenue $664 million to $676 million; adjusted EBITDA $323 million to $335 million; fiscal Q1 revenue $151 million to $152 million
  • Matthew Sonefeldt becomes principal financial officer June 8, 2026; Siddharth Sitaram serves as interim PFO through June 7, 2026
Read the filing on SEC.gov ↗
Apr 17, 4:34 PM ET

Doximity CFO Anna Bryson resigns; Siddharth Sitaram named interim finance chief

Neutral leadership Written later 5.027.01

Doximity disclosed that Chief Financial Officer Anna Bryson, who had been on medical leave, resigned on April 13, 2026, and that Chief Accounting Officer Siddharth Sitaram has served as interim principal financial and accounting officer since February 3, 2026. The company also reaffirmed its guidance for the fourth quarter and full fiscal year ending March 31, 2026, given on February 5, 2026, which matters to shareholders because it signals no change to prior expectations despite the leadership transition.

  • CFO Anna Bryson resigned; the company accepted her resignation on April 13, 2026
  • Siddharth Sitaram, Chief Accounting Officer, serves as interim principal financial and accounting officer, effective February 3, 2026
  • Company reaffirmed fourth quarter and full fiscal year 2026 guidance first given February 5, 2026
  • Company expects to update on the CFO search during its next earnings call
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Recent SEC filings

EDGAR ↗

Famous investors who own DOCS

All investors →
InvestorValue% of portfolioLast quarter
Renaissance Technologies $59.18M0.08% Reduced
Ray Dalio Bridgewater Associates $2.73M0.01% Added

From each investor's latest 13F filing (Q2 2026); positions are as of the quarter end and filed up to 45 days later.

Trades disclosed by members of Congress

All DOCS congressional trades →
TradedMemberTypeAmount
Nov 06, 2025Jonathan Jackson IL-01Sell$15,001 – $50,000
Aug 25, 2025Jonathan Jackson IL-01Buy$15,001 – $50,000

From House periodic transaction reports (STOCK Act); amounts are the form's ranges.

Insider transactions

All insider trades →
DateInsiderTypeSharesPriceValue
Nov 02Wampler Kira Scherer
Director
Sell 10b5-12.00K$32.89$65.78K
Oct 14Sitaram Siddharth
Chief Accounting Officer
Sell 10b5-12.61K$30.68$80.17K
Oct 01Wampler Kira Scherer
Director
Sell 10b5-12.00K$28.91$57.82K
Sep 30Yang Watkin Phoebe L.
Director
Sell 10b5-11.29K$26.71$34.46K
Sep 24Zatz Steven L
President
Award152.43K—$0

Prices are end-of-day and split-adjusted. Financial data from Doximity's SEC XBRL filings. Not investment advice.